Clinical trials: Metastatic Solid Tumor Cancer
Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that…
- Conditions
- Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
- Trial name
- FOCUS-01 (NCT07454642)
- Testing
- AVA6103
- Where
- 7 sites in United States
- Volunteers
- 174 people
- Sponsor
- Avacta Life Sciences Ltd
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
This Phase Ib/II study is an open label, multicenter study. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder…
- Conditions
- Solid Tumor, Breast Cancer, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT01134250
- Testing
- F16IL2 in combination with paclitaxel
- Where
- 5 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Philogen S.p.A.
Breast Cancer
Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005991
- Testing
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer: Recurrent and/or Metastatic Solid Tumours
A Phase I Open-Label, Single-Arm, Dose-Escalation Clinical and Pharmacology Study of CCI-001 as Monotherapy and in Combination With Standard Chemotherapy in Patients With Recurrent and/or Metastatic Solid Tumours
CCI-001 is a novel colchicine derivative that is being developed by PharmaMatrix Holdings Ltd. (PharmaMatrix). The drug binds to tubulin, a component of the microtubule polymers which are required for a wide range of cellular…
- Trial name
- NCT04823897
- Testing
- CCI-001
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- PharmaMatrix Holdings Ltd
Advanced or Metastatic Solid Tumors, Malignancy
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114
A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.
- Conditions
- Advanced or Metastatic Solid Tumors, Malignancy, Metastasis
- Trial name
- NCT05200273
- Testing
- AK114
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Akeso
Solid Tumors
MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors
The main purpose of this Phase I study was to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks.
- Trial name
- NCT02517398
- Testing
- MSB0011359C
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 600 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving stereotactic radiosurgery after surgery may kill any tumor cells that remain after surgery.
- Trial name
- NCT00814463
- Testing
- MMSE, QOL via FACT-Br, MRI
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Duke University
Unspecified Adult Solid Tumor, Protocol Specific
Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors
This research trial studies using genomic profiling to recommend anticancer treatment to patients with cancer that has spread beyond the original site of the tumor (metastatic cancer).
- Trial name
- NCT02215928
- Testing
- mutation analysis, cytology specimen collection procedure, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Stanford University
Solid Tumors
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT00390936
- Testing
- Brivanib
- Where
- Japan
- Volunteers
- 13 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Cancer
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
This is non randomised, open label, dose finding, efficacy and safety study, enrolling patients with advanced (stage III and IV) ovarian cancer It will be conducted in two successive phases. Phase II has a two-step design
- Trial name
- NCT00831636
- Testing
- CP-4055
- Where
- 5 sites in Belgium, Italy
- Volunteers
- 28 people
- Sponsor
- Clavis Pharma
Chronic Myeloproliferative Disorders, Fatigue
American Ginseng in Treating Patients With Fatigue Caused by Cancer
RATIONALE: American ginseng may reduce fatigue in patients with cancer. It is not yet known whether American ginseng is more effective than a placebo in treating cancer-related fatigue.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00719563
- Testing
- American ginseng
- Where
- 326 sites in United States
- Volunteers
- 364 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Solid Tumor Cancer, Metastases
Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
This study evaluates a non-cationic peptide-CD47 siRNA nanocomplex for refractory advanced solid tumors. The candidate blocks the CD47-SIRPα "don't eat me" signal, repolarizes tumor-associated macrophages, and restores antitumor…
- Conditions
- Solid Tumor Cancer, Metastases, Head and Neck Cancer
- Trial name
- NCT07583914
- Testing
- NCP-CD47 siRNA intratumorally injection
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Metastatic Cancer
N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
The metastatic lesions may be very different from the primary tumor because of intrinsic tumor heterogenity, clonal selection through metastatic process and following previous cytotoxic treatments.
- Trial name
- MetAction (NCT02142036)
- Testing
- EMA-approved ATI based targeted therapy
- Where
- 2 sites in Norway
- Volunteers
- 50 people
- Sponsor
- Oslo University Hospital
Refractory and/or Relapsed Metastatic Solid Tumors
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk…
- Trial name
- NCT01804634
- Testing
- Cyclophosphamide, Fludarabine, low dose total body irradiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Solid Cancers
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of orally administered GDC-0941 administered once daily (QD) and twice daily (BID) in the treatment of…
- Trial name
- NCT00876109
- Testing
- GDC-0941
- Where
- 3 sites in United States
- Volunteers
- 108 people
- Sponsor
- Genentech, Inc.
Solid Metastatic Tumor
TCR-engineered T Cells (NW-101C) in Patients With Solid Malignant Tumors
This clinical trial is a prospective, dose-escalation, multicenter, single- arm, Phase 1 clinical trial to evaluate the safety, tolerability, PK and preliminary clinical activity of PRAME Antigen-targeted TCR-T Cells (NW-101C)…
- Trial name
- NCT07266298
- Testing
- NW-101C
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Neowise Biotechnology
Advanced Solid Tumor, Gynecologic Cancer
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of…
- Trial name
- NCT04042116
- Testing
- Lucitanib, Nivolumab
- Where
- 27 sites in United States, Austria and 4 more
- Volunteers
- 227 people
- Sponsor
- Clovis Oncology, Inc.
Metastatic Esophageal, Gastric Cancer
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND).
- Conditions
- Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05075993
- Testing
- LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- M.D. Anderson Cancer Center
BRAF V600 Mutation, Unresectable Melanoma
Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma
Encorafenib in combination with binimetinib have been approved in USA, Europe, Australia, Japan and Switzerland for the treatment of adult patients with unresectable or metastatic melanoma with BRAF V600 mutation.
- Conditions
- BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
- Trial name
- NCT04759846
- Testing
- Encorafenib + Binimetinib
- Where
- 7 sites in Czechia, Italy and 1 more
- Sponsor
- Pierre Fabre Medicament
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.